إعلان
إعلان

JSPR

JSPR logo

Jasper Therapeutics, Inc. Common Stock

1.65
USD
برعاية
-0.40
-19.32%
٠٨ يناير, ١٦:٠٠ UTC -5
مغلق
exchange

بعد الإغلاق

1.66

0.00
+0.06%

تقارير أرباح JSPR

النسبة الإيجابية المفاجئة

JSPR تفوق 9 من 17 آخر التقديرات.

53%

التقرير التالي

بيانات التقرير القادم
٢٥ فبراير ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.68
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
-45.60%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
-58.02%

Jasper Therapeutics, Inc. Common Stock earnings per share and revenue

On ١٠ نوفمبر ٢٠٢٥, JSPR reported earnings of -1.25 USD per share (EPS) for Q3 25, missing the estimate of -1.23 USD, resulting in a -0.87% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a 0.00% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 9 المحللين forecast an EPS of -0.68 USD, with revenue projected to reach -- USD, implying an نقصان of -45.60% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, Jasper Therapeutics, Inc. Common Stock reported EPS of -$1.25, missing estimates by -0.87%, and revenue of $0.00, 0% as expectations.
The stock price moved -- 0%, changed from $1.78 before the earnings release to $1.78 the day after.
The next earning report is scheduled for ٢٥ فبراير ٢٠٢٦.
Based on 9 المحللين, Jasper Therapeutics, Inc. Common Stock is expected to report EPS of -$0.68 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان